BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30531241)

  • 1. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
    Batukbhai BDO; De Jesus-Acosta A
    Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
    Jiang R; Hong X; Zhao Y; Wu W
    Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
    Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in pancreatic neuroendocrine tumors.
    Theochari MS; Syrigos KN; Saif MW
    JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
    Yan J; Yu S; Jia C; Li M; Chen J
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
    Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
    Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical and molecular pathology of pancreatic neoplasms.
    Hackeng WM; Hruban RH; Offerhaus GJ; Brosens LA
    Diagn Pathol; 2016 Jun; 11(1):47. PubMed ID: 27267993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
    De Jesus-Acosta AMC
    Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
    [No Abstract]   [Full Text] [Related]  

  • 12. Genes involved in neuroendocrine tumor biology.
    Hofsli E
    Pituitary; 2006; 9(3):165-78. PubMed ID: 17001466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
    Shi C; Klimstra DS
    Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole genome sequencing of colorectal neuroendocrine tumors and in-depth mutational analyses.
    Wang TT; Lu J; Xu L; Wu H; Lin D; Wu Z; Xiao Y
    Med Oncol; 2020 May; 37(6):56. PubMed ID: 32424617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling mechanisms in neuroendocrine tumors as targets for therapy.
    Zarebczan B; Chen H
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):801-10. PubMed ID: 21095546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is new in the pathology of pancreatic neuroendocrine tumors?].
    Komminoth P; Perren A
    Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.